Pregabalin: Clinical Guide
Pregabalin is a first-line calcium channel α2-δ ligand indicated for neuropathic pain conditions, with a straightforward starting dose of 75 mg twice daily (or 50 mg three times daily), titrated to 150-300 mg/day within 1 week, with renal dose adjustments required for creatinine clearance <60 mL/min. 1, 2
Indications
Pregabalin is FDA-approved for:
- Neuropathic pain associated with diabetic peripheral neuropathy (maximum 300 mg/day in US)
- Postherpetic neuralgia (150-600 mg/day)
- Fibromyalgia (300-450 mg/day)
- Neuropathic pain from spinal cord injury (150-600 mg/day)
- Adjunctive therapy for partial-onset seizures (adults and pediatric patients ≥1 month) 2
Dosing Strategy
Starting Doses by Indication
Diabetic Peripheral Neuropathy:
- Start: 50 mg three times daily (150 mg/day)
- Target: 300 mg/day within 1 week
- Maximum: 300 mg/day (doses >300 mg/day show no additional benefit and worse tolerability) 1, 2
Postherpetic Neuralgia:
- Start: 75 mg twice daily OR 50 mg three times daily (150 mg/day)
- Titrate to 300 mg/day within 1 week
- If inadequate relief after 2-4 weeks at 300 mg/day: increase to 600 mg/day (only in tolerant patients)
- Critical caveat: Reserve doses >300 mg/day only for patients with ongoing pain who tolerate 300 mg/day, as higher doses have significantly more adverse effects 1, 2
Fibromyalgia:
- Start: 75 mg twice daily (150 mg/day)
- Increase to 300 mg/day within 1 week
- Maximum effective: 450 mg/day (600 mg/day shows no additional benefit) 2
Spinal Cord Injury Pain:
- Start: 75 mg twice daily (150 mg/day)
- Increase to 300 mg/day within 1 week
- Maximum: 600 mg/day (after 2-3 weeks if inadequate response at 300 mg/day) 2
Titration Schedule
Standard titration: Increase by 150 mg/day every 3-7 days as tolerated 1. The evidence shows that pregabalin's linear pharmacokinetics make dosing more straightforward than gabapentin, and the initial 150 mg/day dose may provide analgesia more quickly 1. Research demonstrates that dose titration within 45 days significantly improves adherence (2.6 times more likely to achieve MPR ≥0.8) and persistence (4.99 vs 4.04 months) 3.
Renal Dose Adjustments
Mandatory adjustments for CLcr <60 mL/min (pregabalin is 98% renally excreted) 2, 4:
Calculate creatinine clearance using Cockcroft-Gault equation, then adjust:
- CLcr 30-60 mL/min: Reduce total daily dose by 50%
- CLcr 15-30 mL/min: Reduce by an additional 50% (25% of normal dose)
- CLcr <15 mL/min: Further reduce to 12.5% of normal dose
- Hemodialysis patients: Administer supplemental dose immediately after each 4-hour dialysis session (pregabalin is highly dialyzable) 2, 4
Example: For postherpetic neuralgia with CLcr 50 mL/min, instead of 150 mg/day, give 75 mg/day in 2-3 divided doses 2.
Side Effects
Most common (dose-dependent):
- Dizziness (23.1%) - most frequent adverse effect
- Somnolence (14.6%)
- Peripheral edema (10.4%) 5
These are mild-to-moderate and managed by dose reduction without discontinuation 5, 6.
Serious but rare:
- Myoclonus (both positive and negative) - can occur even without renal dysfunction; presents with jerking movements or transient neurological deficits mimicking stroke 7
- Delayed cutaneous hypersensitivity reactions - can occur up to 40 days after initiation (not just within 2 weeks); monitor throughout treatment course 8
- Psychiatric effects: Psychosis, hallucinations, anxiety, depression, sexual disinhibition - intensified by high doses, abrupt withdrawal, or preexisting psychiatric illness 9
- Respiratory depression 7
Abuse potential: Schedule V controlled substance; high risk in substance-dependent patients 6, 9
Tapering Recommendations
Taper gradually over minimum of 1 week when discontinuing 2. Abrupt withdrawal can precipitate withdrawal syndrome and intensify psychiatric symptoms 9. For patients on higher doses or long-term therapy, consider slower tapers to minimize withdrawal effects.
Alternative Therapies
When pregabalin fails or is not tolerated, first-line alternatives include 1:
- Gabapentin (100-300 mg at bedtime, titrate to 3600 mg/day over 3-8 weeks) - similar efficacy but nonlinear pharmacokinetics requiring more complex titration
- Duloxetine (30 mg daily, increase to 60 mg after 1 week, maximum 120 mg/day)
- Tricyclic antidepressants (nortriptyline/desipramine 25 mg at bedtime, titrate by 25 mg every 3-7 days to 150 mg/day)
- Topical 5% lidocaine patch (for well-localized peripheral neuropathic pain with allodynia)
Second-line options: Tramadol, opioid analgesics (reserved for refractory cases due to long-term safety concerns) 1
Note on combination therapy: Evidence for pregabalin combined with gabapentin is lacking; dosing recommendations cannot be offered 1, 2. Guidelines acknowledge sparse evidence for combination therapy generally, though it may be considered in challenging cases at physician discretion 10.
Key Clinical Pearls
- Geriatric patients: Use lower starting doses and slower titration 1
- Treatment duration: Allow 4-week adequate trial at maximum tolerated dose before declaring treatment failure 1
- Refractory patients: Pregabalin shows efficacy in some patients who failed other treatments, including gabapentin 10
- Administration: Can be taken with or without food 2
- Drug interactions: Few significant interactions due to lack of protein binding and hepatic metabolism 1, 6